MedRod® Controlled Drug Release Technology
MedRod® is Registered Trademark of Preclinapps
MedRod® Implant
Delivers the active ingredient in an efficient and reliable manner to support and improve the quality of preclinical studies. MedRod® implant is biostable, it does not degrade or leach out any other compounds than the active ingredient itself, allowing for controlled drug release. MedRod® can be removed at any point of the study if wanted.
Medrod® implants are made from biocompatible medical polymers.
It is stable and cost-effective substitute to chronic injections, leading to improved study outcomes.
MedRod® dosing technology for preclinical animal research
In MedRod® implant the active compounds are dispersed in flexible, polymeric cylindrical rods, optionally covered by membrane or thin membrane coating. The manufacturing process results in soft and elastic MedRod® implant where compound is safely immobilized and steadily released for several months In Vivo. MedRod® implants are intended for in vitro or in vivo preclinical studies.
MedRod® implants have been validated with several immunodeficient mouse strains, including athymic nude, NOG, NSG, balb/c nude and SCID mice as well as with many hormone-dependent breast and prostate cancer cell lines such as, MCF-7, BT-474 and LNCaP cells.
Safe long-term controlled drug release from a week up to years
MedRod® implant has elastic and biocompatible soft drug matrix. Each batch and dosage is validated unlike some competing long-term controlled drug release systems.
Controlled drug release with known daily dose minimizes the risk of toxic or adverse effects of the drug.
Suitable for variety of drug substances
Drug substances such as estrogens, androgens, progestins, glucocorticoids and other small molecules (such as 17beta estradiol, DHT, testosterone) have an excellent continuous drug release profile from MedRod® implants.
Wide concentration range and target animals
Dose range from 10 ng/day even up to 200 mcg/day. Typically used in ER and AR-dependent xenograft, syngeneic and PDX cancer studies and metabolic studies in mice, but also in rats or even larger animals (rabbit, dog, minipig).